摘要
随着2017年首款嵌合抗原受体T细胞(CAR-T)产品上市,免疫细胞治疗跨入新时代,给全球数以万计的肿瘤患者带来了治疗新希望。目前,CAR-T细胞产品已在急性B淋巴细胞白血病、B细胞非霍奇金淋巴瘤、多发性骨髓瘤等血液系统恶性肿瘤治疗中取得了显著效果,在治疗实体瘤和感染性疾病(如HIV感染)中也取得了一定进展。尽管病因不同,部分自身免疫性疾病(AIDs)与血液学肿瘤都可因B淋巴细胞/浆细胞功能异常而发病,CAR-T细胞产品在治疗血液学肿瘤中取得的成功向科学家们提示了其治疗AIDs的潜力。近期CAR-T细胞在系统性红斑狼疮等AIDs的治疗中取得了突破性进展,本文将对基于CAR的细胞疗法在自身免疫性疾病中的应用研究进展进行介绍并对未来的发展方向进行展望。
With the launch of the first Chimeric antigen receptor T cell(CAR-T)therapy in 2017,immune cell therapy has entered a new era,bringing new hope to tens of thousands of tumor patients worldwide.To date,CAR-T therapy has achieved remarkable results in the treatment of hematological malignancies such as acute B-lymphoblastic leukemia,B-cell non-Hodgkin’s lymphoma,multiple myeloma,and some progress has been made in the treatment of solid tumors and infectious diseases such as HIV infection.Although the etiology is different,some autoimmune diseases(AIDs)and hematologic tumors can be caused by B lymphocyte/plasma cell dysfunction.The success of CAR-T cell products in treating hematologic tumors suggests the potential of CAR-T cell products in treating AIDs.Recently,CAR-T cell therapy has made a breakthrough in the treatment of AIDs,such as systemic lupus erythematosus.In this paper,the application of CAR-based cell therapies in autoimmune diseases will be reviewed and the future development direction will be prospected.
作者
王晶
黄云虹
鲁爽
高晨燕
WANG Jing;HUANG Yun-hong;LU Shuang;GAO Chen-yan(Center for Drug Evaluation,National Medical Products Administration,Beijing 100022,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2023年第16期2428-2432,共5页
The Chinese Journal of Clinical Pharmacology
